While Leap Therapeutics Inc has underperformed by -1.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LPTX fell by -85.02%, with highs and lows ranging from $4.79 to $0.48, whereas the simple moving average fell by -80.32% in the last 200 days.
On January 29, 2025, Robert W. Baird Downgraded Leap Therapeutics Inc (NASDAQ: LPTX) to Neutral. A report published by H.C. Wainwright on January 29, 2025, Downgraded its rating to ‘Neutral’ for LPTX. Rodman & Renshaw also rated LPTX shares as ‘Buy’, setting a target price of $8 on the company’s shares in an initiating report dated June 28, 2024. Mizuho Initiated an Buy rating on October 04, 2021, and assigned a price target of $6. Robert W. Baird initiated its ‘Outperform’ rating for LPTX, as published in its report on June 04, 2021. Piper Sandler’s report from June 29, 2020 suggests a price prediction of $6 for LPTX shares, giving the stock a ‘Overweight’ rating. Robert W. Baird also rated the stock as ‘Outperform’.
Analysis of Leap Therapeutics Inc (LPTX)
One of the most important indicators of Leap Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -106.79% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.97, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and LPTX is recording 799.87K average volume. On a monthly basis, the volatility of the stock is set at 11.76%, whereas on a weekly basis, it is put at 6.33%, with a loss of -9.19% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.44, showing growth from the present price of $0.49, which can serve as yet another indication of whether LPTX is worth investing in or should be passed over.
How Do You Analyze Leap Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 25.44%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 30.08% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
LPTX shares are owned by institutional investors to the tune of 30.08% at present.
